Format

Send to

Choose Destination
Cytokine Growth Factor Rev. 2014 Apr;25(2):185-93. doi: 10.1016/j.cytogfr.2013.12.009. Epub 2013 Dec 24.

Death receptor agonist therapies for cancer, which is the right TRAIL?

Author information

1
Therapeutic Innovation Unit, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, United States. Electronic address: hollandp@amgen.com.

Abstract

The activation of cell-surface death receptors represents an attractive therapeutic strategy to promote apoptosis of tumor cells. Several investigational therapeutics that target this extrinsic pathway, including recombinant human Apo2L/TRAIL and monoclonal agonist antibodies directed against death receptors-4 (DR4) or -5 (DR5), have been evaluated in the clinic. Although Phase 1/1b studies provided encouraging preliminary results, findings from randomized Phase 2 studies failed to demonstrate significant clinical benefit. This has raised multiple questions as to why pre-clinical data were not predictive of clinical response. Results from clinical studies and insight into why current agents have failed to yield robust responses are discussed. In addition, new strategies for the development of next generation death receptor agonists are reviewed.

KEYWORDS:

Apo2L/TRAIL; Apoptosis; Cancer; Death receptor

PMID:
24418173
DOI:
10.1016/j.cytogfr.2013.12.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center